| Title |
The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial
|
|---|---|
| Published in |
Diabetologia, December 2011
|
| DOI | 10.1007/s00125-011-2415-y |
| Pubmed ID | |
| Authors |
A. Rafnsson, F. Böhm, M. Settergren, A. Gonon, K. Brismar, J. Pernow |
| Abstract |
Endothelial dysfunction is important in the development of vascular complications in diabetes. Patients with type 2 diabetes have increased production of the vasoconstrictor and pro-inflammatory peptide, endothelin-1. Short-term intra-arterial administration of endothelin antagonists improves endothelium-dependent vasodilatation in patients with type 2 diabetes. We tested the hypothesis that oral administration of the dual endothelin receptor antagonist, bosentan, improves peripheral endothelial function in patients with type 2 diabetes and microalbuminuria. |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Denmark | 1 | 2% |
| Unknown | 59 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 16% |
| Researcher | 9 | 15% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 5 | 8% |
| Other | 4 | 6% |
| Other | 14 | 23% |
| Unknown | 13 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 34% |
| Social Sciences | 5 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Nursing and Health Professions | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 9 | 15% |
| Unknown | 16 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2016.
All research outputs
#7,412,246
of 22,661,413 outputs
Outputs from Diabetologia
#2,820
of 5,023 outputs
Outputs of similar age
#70,508
of 243,645 outputs
Outputs of similar age from Diabetologia
#24
of 54 outputs
Altmetric has tracked 22,661,413 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,023 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.6. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,645 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.